Introduction
cessfully in several models of IL-1-related pathologies, Interleukin 6 (IL-6) is a multifunctional helical cytokine such as rheumatoid arthritis. 13 and plays a central role as a differentiation and growth 'Artificial' hIL-6 receptor-superantagonists were factor of hematopoietic precursor cells, B cells, T cells, obtained by incorporating two sets of aminoacid substineuronal cells, osteoclasts and endothelial cells, 1 and tutions in regions of the molecule responsible for receptor modulates transcription of several liver-specific genes binding: (1) antagonistic substitutions required to selecduring acute inflammation. 2 Sequential interaction of ILtively impair interaction between the protein and the sig-6 with the receptor subunits gp80 and gp130, induces a nal transducing subunit of the receptor, gp130; and (2) cascade of events, mediated by the family of JAK kinases, superbinder substitutions required for higher binding leading to the activation of specific transcription factors. 3 affinity to the IL-6 receptor subunit, gp80.
14 IL-6 receptor Altered IL-6 serum levels have been reported in several superantagonists are of great therapeutic potential, pathologies, such as multiple myeloma, 4 Castleman's disespecially because of their potency, that permits efficient ease, 5 osteoporosis, 6 EBV positive lymphomas 7 and rheu-IL-6-blocking at low doses. The use in vivo of therapeutic matoid arthritis. 8 In multiple myeloma, IL-6 clearly plays proteins is limited by the short half-life of the molecules an autocrine and/or paracrine role in the growth of and by the high doses required for clinical purposes. malignant cells. 4 Further hindrance is that the therapeutic action of the Anti-IL-6 monoclonal antibodies (mAbs) have been protein cannot be directed to a specific tissue. Adenoproposed as therapeutic tools for IL-6-related pathovirus gene therapy seems the most suitable system for logies. 4, 7, 9 However, it has been shown in multiple myeldelivery of such therapeutic genes in vivo, as it has been oma that antibodies can stabilize IL-6 in the form of circushown to be a very effective vector for transient gene lating complexes, creating the so-called 'paradoxical transfer of both intracellular and secretable proteins. A effect'. 10, 11 The use of receptor antagonists rather than wide range of cells are susceptible to Ad infection, high mAbs, is an innovative and promising approach for the virus titers are readily obtainable and extremely treatment of cytokine-mediated disease states. These molefficacious gene transfer has been described in several ecules act by specifically binding cytokine receptors in animal models. 15 competition with their natural ligand. A natural IL-1 We used defective adenovirus, deleted in the E1 and E3 regions, as a vector for the construction of a recombinant particle containing IL-6 receptor superantagonist cDNA, under the control of the strong RSV promoter. In this Bioactivity of hIL-6-␣ expressed in vitro: experiments on Results liver cells Liver cells are a major target for IL-6. During inflamExpression of hIL-6-␣ in virally infected cells mation, many liver-derived proteins are increased in conThe recombinant adenoviral vector AdRSVhIL6␣ was centration to provide enhanced protection against invadconstructed by inserting the cDNA coding for the hILing micro-organisms, limit tissue damage and promote 6 receptor antagonist Sant1 (Y31D, G35F, S118R, V121D, rapid return to homeostasis. These proteins, called acute Q175I, S176R, Q183A hIL-6), 15 with wild-type (wt) IL-6 phase proteins (APP) include serum amyloid protein, C leader peptide sequence, under the control of the strong reactive protein (CRP) and haptoglobin. The transcription RSV promoter, into a viral backbone devoid of most E1 of APP genes is under the control of cytokine-inducible and E3 sequence. To test antagonist expression, human promoters. 16 Conditioned medium from 293 cells infected embryonic kidney 293 cells were infected with 5 p.f.u. with 10 p.f.u. per cell of AdRSVhIL6␣, was analyzed on per cell of a purified AdRSVhIL6␣ stock. After 24 h, contwo human hepatic cell lines, Hep3B and HepG2. Cells ditioned medium was collected, concentrated and anawere transfected with a construct containing as reporter lyzed by Western blot. As shown in Figure 1 , a single gene a secretable form of alkaline phosphatase (SEAP), band of the expected molecular mass was detected in the under the control of the inducible CRP gene promoter. supernatants of AdRSVhIL6␣-infected cells. No detectAfter treatment of cells with cytokines, SEAP activity was able signal was observed in the supernatants of cells monitored. Hep3B cells were treated with 4 ng/ml of infected with AdRSV␤gal, or in mock-infected cells.
wild-type hIL-6 in the presence or absence of conditioned Antagonist production in the supernatants of infected 293 medium, SEAP activity was measured in cell supercells was quantified by ELISA. Twenty-four hours after natants. As shown in Figure 2a , the medium of cells infection of 293 with AdRSVhIL-6␣ at MOI 10, the coninfected with AdRSVhIL6␣ was able to inhibit hIL-6-centration of antagonist in conditioned medium ranged induced CRP promoter activity in a dose-dependent from 0.5 to 1 g/ml (data not shown).
manner. In the same bioassay, the effect obtained using equivalent doses of Sant1 produced in E. coli and purified to homogenicity, is comparable. The inhibitory effect observed when using supernatants of infected cells was not due to toxicity since in the presence of a molar excess of hIL-6 promoter activity was rescued up to 100% (data not shown). The specificity of the effect of AdRSVhIL6␣-conditioned medium on CRP promoter activation was analyzed in the same bioassay, testing the inhibitory potential of conditioned medium on human oncostatin M (hOSM)-induced activation of the same promoter in the hepatic line HepG2. OSM is a member of the IL-6 cytokine family also as leukemia inhibitory factor, ciliary neurotrophic factor and interleukin 11. This group of cytokines uses the trasmembrane protein gp130 as common signal transducer, and different receptor ␣ subunits to mediate the specificity of bioactivity; 3 therefore only if the interaction of the antagonist is highly specific for the IL-6 receptor ␣ chain, the inhibitory effect should not be observed on OSM-induced cell activation. As shown in Figure 2b , CRP activity can be stimulated in HepG2 cells by comparable amounts of hIL-6 or of hOSM (4 ng/ml), but, as expected, supernatants of cells infected with AdRSVhIL6␣ inhibited only hIL-6-induced activation. Specificity of conditioned media bioactivity was further analyzed on HepG2 cells, studying the activation of the IL-6-type cytokine-induced acute phase transcription factor (APRF), STAT3. Following the interaction of the cytokines belonging to the IL-6 family with their receptors, one of the first steps in the intracellular signalling pathway, is tyrosine phosphorylation of APRF. Upon phosphorylation, APRF acquires the ability to bind specific DNA sequences (APREs) and migrates to the nucleus. 17 In Figure 3 are shown the results of a band-shift assay performed on HepG2 cells. Cells were treated with hIL-6 or hOSM in the presence or absence of hIL-6 receptor superantagonist, both in the form of purified protein of the purified protein and of conditioned medium is 
circles) and purified Sant1 (white circles), were tested at different dilutions on Hep3B cells transfected with the IL-6-inducible CRP-SEAP construct and induced with 4 ng/ml wt hIL-6. SEAP activity was quantified and
Bioactivity of hIL-6-␣ expressed in vitro: experiments on treated with a fixed dose of wild-type hIL-6, 0.1 ng/ml, in the presence or absence of increasing dilutions of 293 cells conditioned medium. As shown in the Figure, supernatants of 293 infected with the recombinant virus expressing hIL-6 antagonist were able to specifically gene is expressed in immunocompetent mice up to 21 days, and in immunodeficient mice at least 50 days after the injection. The concentration of antagonist in the sera reaches a peak of 1-2 ng/ml in both animal models. As described in the literature, adenovirus-mediated in vivo expression of the transgene in immunocompetent animals is limited to 2-10 weeks, depending on the mice strain, in immunodeficient mice it is of several months, because of the absence of the immunological response, normally responsible for the elimination of adenovirusinfected cells. 19 Since the order of magnitude of expression of antagonist in the two animal models is comparable, it seems that the immune response present in immunocompetent mice has an effect on the length but not on the level of transgene expression. sera, whole extracts were prepared and APRF activation was monitored by gel retardation. As this Figure demon inhibit hIL-6-induced proliferation of the human myelstrates, sera of mice injected with AdRSVhIL6␣ specifioma cell line in a dose-dependent manner. The effect is cally inhibited APRF activation. The inhibitory effect not due to toxicity of the supernatant, since Xg1 proliferobserved in this bioassay is not due to serum toxicity, as ation was rescued by treating the cells with a molar IL-6 bioactivity can be rescued by adding an excess dose excess of hIL-6 (data not shown). As shown in the Figure, of the cytokine (data not shown). These results show that results obtained with the purified protein produced in E.
AdRSVhIL6␣ mediated the direct in vivo production of coli are comparable to those obtained with supernatants a bioactive antagonist. This is important information of infected cells.
for the validation of the potential of this system for therapeutic applications to IL-6-dependent diseases. In vivo expression of hIL-6␣ C57Bl/6 and CB17-scid mice were injected with 2 × 10 9 p.f.u. of recombinant AdRSVhIL6␣ in the orbital vein. Sera were collected at different times after the injection and analyzed in ELISA. As shown in Figure 5 , the trans- significantly reduce their therapeutic potential. Receptor Discussion binding antagonists appear to be more promising effecIn this report we provide data on the adenovirustors for the therapy of cytokine-related diseases. The mediated expression and bioactivity of a human IL-6 mutant described in this work is a hIL-6 receptor superreceptor antagonist. Gene transfer and expression were antagonist, ie the molecule is not bioactive, but binds to accomplished with an adenoviral vector, a vector system hIL-6 receptor ␣ subunit with higher affinity than the generally accepted as having clinical potential for therapy wild-type protein. 14 Hence low molar excess of the antagof human diseases. The authenticity and biological onist over wt IL-6 is sufficient to block cytokine activity. activity of the human IL-6 receptor antagonist expressed
In the perspective of therapeutic application, these from this vector were verified through in vitro and in vivo characteristics would be highly advantageous, not only analysis. The specificity of antagonist activity was anabecause of the high doses of IL-6 present in the sera of lyzed extensively: the inhibitory activity of conditioned patients affected by IL-6-related diseases, but also medium was observed on cells activated with hIL-6 but because of the increase in the levels of circulating soluble not on cells stimulated with a cytokine belonging to the IL-6-receptor observed in some patients. 30, 31 In this report same family, hOSM, in two different bioassays. Ex vivo we show that AdRSVhIL6␣-infected cells produce sigtesting of infected sera on a human multiple myeloma nificant amounts of hIL-6 antagonist both in vitro and in cell line shows the potential efficacy of AdRSVhIL6␣ for vivo, and are capable of inhibiting IL-6 activity in an ILtherapeutic purposes. The superantagonist used in this 6-dependent myeloma human cell line. After injection of study is specific for the human receptor, and thus no 2 × 10 9 p.f.u., the in vivo concentration of the transgene functional competition could be shown directly in vivo on product, both in immunocompetent and immunoa murine IL-6 receptor. None the less, we are currently deficient mice, is in the nanomolar range, which exceeds testing in vivo the recombinant virus in an animal model serum IL-6 levels measured in animal models of IL-6-of a human IL-6-related disorder. related diseases. 7 Furthermore since recombinant first Acute inflammation induced by excess doses of generation adenovirus can be readily obtained at titers of inflammatory cytokines in the serum is the primary or 10
11
-10 12 p.f.u. per milliliter, AdRSVhIL6␣ could be clinisecondary cause of clinical symptoms in several pathocally applied to myeloma and post-transplant lymphoma logies, and AdRSVhIL6␣ is an important candidate for patients where the concentration of circulating hIL-6 in therapy of acute inflammation-related diseases. As the serum is in the picomolar range. 32, 33 shown in this report through the analysis on liver cells, As shown in this report the antagonist can be adenovirus-mediated expression of the hIL-6 receptor expressed in vivo for several weeks in immunocompetent antagonist specifically inhibited inflammation-related animals. Gene therapy thus seems a suitable system for phenomenona, ie stimulation of the acute phase protein delivering such a molecule for therapeutic purposes. It promoter, CRP, and activation of the acute phase tranhas to be underlined that when microgram amounts of scription factor, APRF. The insertion of an IL-6 receptor purified protein are injected intravenously into mice, the antagonist gene in Ad vectors for gene transfer is also a antagonist's half-life is of only a few hours; hence even promising strategy for improving adenovirus-mediated gene therapy itself. When adenovirus is injected in vivo, repeated injections of the protein would probably be inefacute liver inflammation is observed; since it constitutes fective for treatment of diseases characterized by a conthe first response of the host to Ad, it represents a major tinuous cytokine-mediated stimulation of malignant cell factor limiting transgene expression. 20, 21 In order to proliferation, such as multiple myeloma. reduce this adenovirus-induced response, the use of As shown for other transgenes, adenovirus mediates immunosuppressors 22 such as cyclosporin 23 or mAbs efficient but transient expression in immunocompetent directed towards different components of the immune animals. In the context of this study, this could be advansystem, 24, 25 have been proposed. McCoy and co-workers 21 tageous for two reasons. The first is that, as discussed recently described the implementation of AdRSVIL1r␣ in above, the therapeutic targets for a cytokine antagonist mice. This failed to reduce adenovirus-induced pulmonare not genetic diseases, and the second is that IL-6 plays ary inflammation, but transgene expression was observed a physiological role in the organism. Studies on IL-6-for longer than other recombinant adenovirus. In the case deficient mice have shown that, even though these mice of adeno-induced inflammation, an IL-6 antagonist is develop normally, specific functions of the immune sysmore specific and potentially more effective than an ILtem are impaired. 34 Therefore temporary rather than life1r␣. In fact, when adenovirus is injected into animals, ILtime inactivation of this cytokine is more suitable for 6 is the first cytokine to be detected, and its levels in the clinical purposes. sera are higher than those of other soluble mediators of
The gene therapy approach potentially allows for a inflammation such as IL-1 and TNF-␣. [25] [26] [27] controlled and intracellular expression of the antagonist, Anti-IL-6 strategies would also appear very promising the latter being of interest for the inhibition of for the treatment of IL-6-dependent malignancies. As cytoplasmic interaction between ligand and receptor. described in the literature, IL-6 plays a critical autocrine This interaction would seem to play an important and paracrine role in the growth of several tumours. 1, 28 role in the autocrine loop of IL-6-dependent cell Anti-IL-6 mAbs have been used in phase one and two proliferation. 35 clinical trials for therapy of multiple myeloma, and have The combination of the specific features of the antagonbeen proven, at least in some patients, to be effective. 9, 29 ist used in this work, with the adenovirus gene therapy mAbs, and more generally cytokine-binding proteins, approach, that allows efficient in vivo bioactive transgene have however some limitations in therapy. In fact the expression, appears to be a very promising strategy for immunogenicity of mAbs and the so-called 'paradoxical the therapy of IL-6-related pathologies. CRP promoter assay S118R, V121D, Q175I, S176R, Q183A) hIL-6 cDNA 14 was Transcriptional activation of the CRP gene promoter in subcloned together with hIL-6 leader sequence in the Hep3B or HepG2 cells was determined and quantified as adenoviral vector pAdRSV␤gal restricted SalI/EcoRV. 36 described. 40 Briefly, 1 × 10 5 HepG2 or 5 × 10 4 Hep3B cells Recombinant plasmid was cotransfected together with were plated in 24 multiwell plates (Falcon, SIAL, Rome, ClaI-restricted AdRSV␤gal genome into 293 cells (ATCC, Italy). After 5 h cells were induced with 4 ng/ml hIL-6 Rockville, MD, USA). Recombinant plaques were isolated or 4 ng/ml hOSM, in the presence or absence of superand amplified as previously described. 37, 38 DNA pattern natants of infected cells or of purified antagonist. SEAP of recombinant AdRSVhIL6␣ was analyzed by multiple activity in the supernatant of cells was assayed, as prerestriction.
viously described, with a colorimetric reaction using a AdRSV␤gal and AdRSVh␣␣t construction has been substrate p-nitrophenylphosphate (Sigma, Milan, Italy). described previously. 36, 39 The A405 of the reaction mixture was recorded with a All viral stocks were prepared in 293 cells and purified Bio-Rad model 450 automatic plate reader (Bio-Rad, Ivrytwice on isopicnic CsCl gradient. Desalting was perforsur-Seine, France). med using Pharmacia G50 columns (Orsay, France). Viruses were divided into aliquots and kept in PBS-15% XG-1 proliferation assay glycerol at −80°C. Titers, calculated by plaque analysis on XG-1 cells were cultured as described 19 in the presence 293 cells, varied from 1 to 2 × 10 11 p.f.u. per milliliter. of 2 ng/ml of hIL-6. To test supernatants of cells infected with AdRSVhIL6␣ or of purified Sant1 for antagonistic Animals behavior, cells (6 × 10 3 per microwell, in 96-well microC57Bl/6 mice or CB-17-scid mice 6 to 8 weeks old were titer plates; Falcon) were cultured in 200 l of RPMI 1640 purchased from IFFACREDO (L'Arbresle, France). The supplemented with 10% fetal calf serum and 5 × 10 −5 m animals were treated according to the institutional guide-␤-ME with serial dilutions of supernatant or Sant1, in the lines. Mice were injected in the orbital vein with purified presence of 0.1 ng/ml of wt hIL-6. After 7 days, cell numvirus, diluted in 100 l of PBS. Sera were collected by bers were evaluated by colorimetric determination of puncturing the orbital vein after treating the animal with hexosaminidase levels, according to Landegren. 41 ether. After short centrifugation blood supernatants were kept at −20°C. Balb/c mice were bred at IRBM (Pomezia, ElectroMobility Shift Assays (EMSAs) Italy). Serum was collected by intracardiac puncture, For HepG2, 10 6 cells per well were plated in 6-multiwell after the death of the animals.
plates (Falcon). Cells were induced with 2 ng per well hIL-6 or 2 ng/ml hOSM, in the presence or absence of Immunodetection of IL-6 antagonist 600 ng/ml antagonist, either in the form of pure protein obtained from bacteria, or as conditioned medium from Western blot: 35-mm Falcon plates of subconfluent 293
AdRSVhIL6␣-infected cells. For Xg1, cells were washed cells were infected with AdRSVhIL6␣ or AdRSVh␣␣t, at twice with culture medium, incubated for 4-5 h at 37°C MOI 5 in 3 ml of medium. Twenty-four hours after infecin culture medium without hIL-6 and washed twice again tion, supernatants were collected and concentrated fivein 1 × PBS. 2 × 10 6 Cells in 400 l of culture medium were fold with centrex UF filters (Scleicher and Schuell, Ecqueadded to each sample (500 l of serum +100 l RPMI villy, France). Twenty-five microliters of concentrated with or without hIL-6 0.2 ng/ml). For the control samples supernatants were loaded on acrylamide gel. The gel was (no hIL-6 and hIL-6 0.2 ng/ml), sera from control electroblotted and nitrocellulose membrane was blocked BALB/c mice were used. Both control sera from BALB/c overnight in TBS-5% milk-0.05% Tween 20. After washmice and sera from adeno-injected scid mice were concening in TBS-0.05% Tween 20, the membrane was incubated trated 1.5-fold in centrex UF filters prior to their utiliz-2 h with a polyclonal serum anti-hIL-6 (hIL-6 ELISA kit, ation. HepG2 or XG-1 cells were collected after 15 min of R&D, Oxford, UK), coupled to horseradish peroxidase, induction at 37°C, rinsed with ice-cold PBS containing 5 diluted 1:2, v/v, in TBS-5% milk-0.05% Tween 20. After mm NaF, centrifuged and cell pellets were frozen in washing with TBS-0.05% Tween 20, the membrane was liquid nitrogen. Total cell extracts were prepared as prerevealed with ECL bioluminescence kit (Amersham, UK).
viously described. 15 STAT activation was monitored by hIL-6, hOSM and Sant1 purified from bacteria, were binding to the high affinity SIE m67 oligonucleotide, 42 prepared as previously described.
14 which was labeled by filling in 5′ protruding end with T7 DNA polymerase (Boehringer Mannheim, Meylan, ELISA: ELISA was performed on supernatants of infected France), using ␣-32 P-dATP and ␣-32 P-dCTP (3000 cells and on mice sera with the IL-6 detection kit Ci/mmol). EMSA were performed according to purchased from R&D.
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